X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-03-13 | PROK | Prokidney Corp. | Control Empresarial De Capitales S.A. De C.V. | Add'l Rep. Persons-see Ex.99-1, 10% | P - Purchase | $1.42 | +177,000 | 63,295,645 | 0% | +$251,666 | |||||
2024-05-15 | DNA | Ginkgo Bioworks Holdings, Inc. | Sankar Shyam | Dir | P - Purchase | $0.82 | +625,000 | 2,356,874 | +36% | +$514,750 | ||||||
| D | 2024-05-14 | RGNX | Regenxbio Inc. | Mills Kenneth T. | Pres, CEO | S - Sale+OE | $15.81 | -15,000 | 408,035 | -4% | -$237,222 | |||||
| D | 2024-05-14 | NBIX | Neurocrine Biosciences Inc | Lyons Gary A | Dir | S - Sale+OE | $135.63 | -12,500 | 116,947 | -10% | -$1,695,370 | |||||
| DM | 2024-05-14 | NBIX | Neurocrine Biosciences Inc | Abernethy Matt | CFO | S - Sale+OE | $137.95 | -30,000 | 31,528 | -49% | -$4,138,436 | |||||
2024-05-14 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $10.12 | -20,054 | 7,198,360 | 0% | -$202,934 | ||||||
| D | 2024-05-14 | TECH | Bio-Techne Corp | Higgins John L | Dir | S - Sale+OE | $83.84 | -4,000 | 36,608 | -10% | -$335,377 | |||||
| D | 2024-05-14 | NVAX | Novavax Inc | Dubovsky Filip | Pres, R, D | S - Sale+OE | $13.90 | -47,312 | 38,953 | -55% | -$657,637 | |||||
| D | 2024-05-13 | EXEL | Exelixis, Inc. | Wyszomierski Jack L | Dir | S - Sale+OE | $21.37 | -10,923 | 338,948 | -3% | -$233,425 | |||||
2024-05-15 | HUMA | Humacyte, Inc. | Binder Gordon M | Dir | P - Purchase | $6.68 | +100,000 | 210,000 | +91% | +$667,500 | ||||||
2024-05-14 | LENZ | Lenz Therapeutics, Inc. | Chevallard Daniel R. | CFO | P - Purchase | $15.68 | +3,188 | 3,188 | New | +$49,988 | ||||||
| M | 2024-05-13 | AVRO | Avrobio, Inc. | Leonard Braden Michael | 10% | P - Purchase | $1.27 | +766,635 | 5,168,262 | +17% | +$971,493 | |||||
2024-05-14 | BCRX | Biocryst Pharmaceuticals Inc | Doyle Anthony | CFO | P - Purchase | $5.57 | +36,300 | 266,744 | +16% | +$202,191 | ||||||
2024-05-14 | BCRX | Biocryst Pharmaceuticals Inc | Thackray Helen M. | Chief R, D Officer | P - Purchase | $5.86 | +30,000 | 272,139 | +12% | +$175,800 | ||||||
2024-05-13 | BCRX | Biocryst Pharmaceuticals Inc | Galson Steven K | Dir | P - Purchase | $5.49 | +21,940 | 51,551 | +74% | +$120,451 | ||||||
2024-05-13 | BCRX | Biocryst Pharmaceuticals Inc | Barnes Alane P | GC | P - Purchase | $5.53 | +5,000 | 300,762 | +2% | +$27,650 | ||||||
2024-05-13 | BCRX | Biocryst Pharmaceuticals Inc | Stonehouse Jon P | Pres, CEO | P - Purchase | $5.55 | +30,000 | 1,167,770 | +3% | +$166,500 | ||||||
2024-05-13 | BCRX | Biocryst Pharmaceuticals Inc | Gayer Charles K | Chief Commercial Officer | P - Purchase | $5.47 | +30,000 | 307,533 | +11% | +$164,100 | ||||||
2024-05-13 | LENZ | Lenz Therapeutics, Inc. | McCollum James W | Dir | P - Purchase | $15.99 | +31,332 | 620,599 | +5% | +$501,093 | ||||||
2024-05-14 | DNA | Ginkgo Bioworks Holdings, Inc. | Sloan Harry | Dir | P - Purchase | $0.91 | +297,619 | 718,540 | +71% | +$271,815 | ||||||
2024-05-14 | DNA | Ginkgo Bioworks Holdings, Inc. | Dekkers Marijn E | Dir | S - Sale | $0.93 | -1,727,056 | 6,061,581 | -22% | -$1,606,162 | ||||||
2024-05-13 | EDIT | Editas Medicine, Inc. | Hopfield Jessica | Dir | P - Purchase | $5.64 | +45,000 | 67,700 | +198% | +$253,868 | ||||||
| D | 2024-05-13 | LXEO | Lexeo Therapeutics, Inc. | Townsend Richard Nolan | CEO | S - Sale+OE | $13.22 | -5,000 | 170,695 | -3% | -$66,093 | |||||
| D | 2024-05-10 | MRNA | Moderna, Inc. | Hoge Stephen | Pres | S - Sale+OE | $120.96 | -255 | 1,642,557 | 0% | -$30,844 | |||||
2024-05-08 | MRNA | Moderna, Inc. | Afeyan Noubar | Dir | S - Sale | $121.68 | -15,000 | 11,677,969 | 0% | -$1,825,220 | ||||||
| M | 2024-05-09 | TARA | Protara Therapeutics, Inc. | Opaleye Management Inc. | 10% | S - Sale | $3.11 | -182,300 | 2,380,294 | -7% | -$566,951 | |||||
2024-05-08 | CVM | Cel Sci Corp | Watson Robert Eugene | Dir | P - Purchase | $1.39 | +20,000 | 24,431 | +451% | +$27,800 | ||||||
2024-05-08 | CVM | Cel Sci Corp | Prichep Patricia B | SVP | P - Purchase | $1.39 | +8,000 | 232,326 | +4% | +$11,120 | ||||||
2024-05-08 | CVM | Cel Sci Corp | Kersten Geert R | CEO | P - Purchase | $1.39 | +30,000 | 1,195,309 | +3% | +$41,700 | ||||||
| DM | 2024-05-06 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Chief Scientific Officer | S - Sale+OE | $28.25 | -63,606 | 129,582 | -33% | -$1,796,676 | |||||
| D | 2024-05-06 | ECL | Ecolab Inc. | Higgins Arthur J | Dir | S - Sale+OE | $227.52 | -4,500 | 25,548 | -15% | -$1,023,854 | |||||
| D | 2024-05-06 | NBIX | Neurocrine Biosciences Inc | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $140.55 | -273 | 7,507 | -4% | -$38,370 | |||||
2024-05-06 | FRTX | Fresh Tracks Therapeutics, Inc. | Exploration Capital, LLC | 10% | P - Purchase | $0.89 | +320 | 1,273,024 | 0% | +$285 | ||||||
2024-05-06 | IPSC | Century Therapeutics, Inc. | Russotti Gregory | See Remarks | S - Sale | $3.12 | -5,000 | 385,092 | -1% | -$15,619 | ||||||
2024-05-03 | IPSC | Century Therapeutics, Inc. | Carr Douglas | SVP Finance, Operations | S - Sale | $3.11 | -257 | 317,323 | 0% | -$798 | ||||||
2024-05-03 | IPSC | Century Therapeutics, Inc. | Farid Adrienne | Chief Operations Officer | S - Sale | $3.11 | -913 | 137,236 | -1% | -$2,836 | ||||||
2024-05-03 | ALVR | Allovir, Inc. | Brainard Diana | CEO | S - Sale | $0.80 | -10,240 | 792,695 | -1% | -$8,151 | ||||||
2024-05-03 | ALVR | Allovir, Inc. | Hagen Brett R | Chief Accounting Officer | S - Sale | $0.80 | -1,597 | 76,022 | -2% | -$1,271 | ||||||
2024-05-03 | ALVR | Allovir, Inc. | Sinha Vikas | See Remarks, 10% | S - Sale | $0.80 | -4,957 | 17,807,905 | 0% | -$3,946 | ||||||
2024-05-03 | ALVR | Allovir, Inc. | Miller Edward | GC | S - Sale | $0.80 | -2,311 | 509,715 | 0% | -$1,840 | ||||||
2024-05-03 | TWST | Twist Bioscience Corp | Banyai William | See Remark | S - Sale | $37.13 | -798 | 345,188 | 0% | -$29,633 | ||||||
2024-05-03 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $37.13 | -568 | 80,436 | -1% | -$21,092 | ||||||
2024-05-03 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $37.13 | -910 | 91,511 | -1% | -$33,792 | ||||||
| D | 2024-05-03 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $37.13 | -4,163 | 509,986 | -1% | -$154,589 | |||||
2024-05-03 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $37.13 | -132 | 43,548 | 0% | -$4,902 | ||||||
2024-05-03 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $37.13 | -2,311 | 173,895 | -1% | -$85,817 | ||||||
2024-05-06 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.41 | +61,729 | 778,184 | +9% | +$25,000 | ||||||
2024-05-06 | AIM | Aim Immunotech Inc. | Rodino Peter W III | COO, Secretary, Gen. Counsel | P - Purchase | $0.41 | +30,865 | 212,583 | +17% | +$12,500 | ||||||
| D | 2024-05-02 | SLDB | Solid Biosciences Inc. | Ganot Ilan | Dir | S - Sale+OE | $10.33 | -462 | 123,708 | 0% | -$4,772 | |||||
| D | 2024-05-02 | DNA | Ginkgo Bioworks Holdings, Inc. | Dmytruk Mark E. | See Remarks | S - Sale+OE | $0.85 | -47,806 | 925,400 | -5% | -$40,396 | |||||
| D | 2024-05-02 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | See remarks | S - Sale+OE | $0.85 | -131,928 | 162,527 | -45% | -$111,479 | |||||
2024-05-03 | AMGN | Amgen Inc | Grygiel Nancy A. | SVP, CCO | S - Sale | $313.09 | -2,117 | 9,983 | -17% | -$662,802 | ||||||
| D | 2024-05-03 | RVMD | Revolution Medicines, Inc. | Anders Jack | CFO | S - Sale+OE | $40.03 | -10,000 | 101,959 | -9% | -$400,260 | |||||
| M | 2024-05-01 | HLVX | Hillevax, Inc. | Kohli Aditya | Dir | S - Sale | $14.03 | -6,898 | 782,878 | -1% | -$96,770 | |||||
2024-05-01 | MRNA | Moderna, Inc. | Afeyan Noubar | Dir | S - Sale | $110.92 | -15,000 | 11,692,969 | 0% | -$1,663,855 | ||||||
| D | 2024-05-02 | DTIL | Precision Biosciences Inc | Scimeca Dario | GC, Secretary | S - Sale+OE | $10.32 | -272 | 5,680 | -5% | -$2,807 | |||||
| D | 2024-05-02 | DTIL | Precision Biosciences Inc | Smith J. Jefferson | Chief Research Officer | S - Sale+OE | $10.32 | -154 | 75,544 | 0% | -$1,589 | |||||
| D | 2024-05-02 | DTIL | Precision Biosciences Inc | List Alan | Chief Medical Officer | S - Sale+OE | $10.32 | -290 | 4,488 | -6% | -$2,993 | |||||
| D | 2024-05-02 | DTIL | Precision Biosciences Inc | Amoroso Michael | Pres, CEO | S - Sale+OE | $10.32 | -1,526 | 13,772 | -10% | -$15,748 | |||||
| DM | 2024-05-01 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $8.10 | -100,000 | 834,820 | -11% | -$810,000 | |||||
| D | 2024-05-01 | ACLX | Arcellx, Inc. | Heery Christopher | CHIEF MEDICAL OFFICER | S - Sale+OE | $51.33 | -18,168 | 8,938 | -67% | -$932,557 | |||||
| M | 2024-05-01 | FRTX | Fresh Tracks Therapeutics, Inc. | Exploration Capital, LLC | 10% | P - Purchase | $0.92 | +164,897 | 1,272,723 | +15% | +$151,680 | |||||
| D | 2024-05-01 | PCVX | Vaxcyte, Inc. | Eydelman Mikhail | SVP, GC, Corp Sec | S - Sale+OE | $61.74 | -1,667 | 30,597 | -5% | -$102,921 | |||||
2024-05-01 | PCVX | Vaxcyte, Inc. | Wassil Jim | COO | S - Sale | $61.65 | -3,000 | 215,462 | -1% | -$184,942 | ||||||
2024-05-01 | PCVX | Vaxcyte, Inc. | Pickering Grant | CEO | S - Sale | $61.70 | -2,616 | 623,901 | 0% | -$161,419 | ||||||
2024-04-30 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $7.95 | -11,447 | 7,218,414 | 0% | -$90,964 | ||||||
2024-05-01 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | CEO | S - Sale | $9.11 | -2,431 | 187,471 | -1% | -$22,152 | ||||||
| D | 2024-04-30 | DTIL | Precision Biosciences Inc | List Alan | Chief Medical Officer | S - Sale+OE | $10.03 | -238 | 3,796 | -6% | -$2,386 | |||||
2024-04-29 | RLAY | Relay Therapeutics, Inc. | Rahmer Peter | See remarks | S - Sale | $6.38 | -1,345 | 513,334 | 0% | -$8,581 | ||||||
2024-04-29 | RLAY | Relay Therapeutics, Inc. | Adams Brian | GC | S - Sale | $6.38 | -1,623 | 325,767 | 0% | -$10,355 | ||||||
2024-04-29 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | CFO | S - Sale | $6.38 | -1,695 | 339,803 | 0% | -$10,814 | ||||||
2024-04-29 | RLAY | Relay Therapeutics, Inc. | Bergstrom Donald A | Pres, R, D | S - Sale | $6.38 | -2,686 | 527,427 | -1% | -$17,137 | ||||||
| D | 2024-04-25 | RXRX | Recursion Pharmaceuticals, Inc. | Marriott Tina | Pres, COO | S - Sale+OE | $7.67 | -3,000 | 543,231 | -1% | -$23,021 | |||||
2024-04-24 | MRNA | Moderna, Inc. | Afeyan Noubar | Dir | S - Sale | $108.32 | -15,000 | 11,707,969 | 0% | -$1,624,836 | ||||||
2024-04-24 | IMVT | Immunovant, Inc. | Geffner Michael | Chief Medical Officer | S - Sale | $28.90 | -3,261 | 141,616 | -2% | -$94,243 | ||||||
2024-04-24 | IMVT | Immunovant, Inc. | Stout Jay S | CTO | S - Sale | $28.90 | -7,239 | 147,739 | -5% | -$209,207 | ||||||
2024-04-24 | IMVT | Immunovant, Inc. | Levine Mark S. | GC | S - Sale | $28.90 | -3,963 | 343,156 | -1% | -$114,531 | ||||||
| D | 2024-04-23 | PCVX | Vaxcyte, Inc. | Pickering Grant | CEO | S - Sale+OE | $61.92 | -15,000 | 772,571 | -2% | -$928,845 | |||||
2024-04-23 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $30.12 | -2,174 | 176,206 | -1% | -$65,483 | ||||||
2024-04-22 | ZURA | Zura Bio Ltd | Howell Michael | See Remarks | P - Purchase | $3.13 | +7,987 | 122,382 | +7% | +$24,999 | ||||||
2024-04-22 | ZURA | Zura Bio Ltd | Nistala Kiran | EVP | P - Purchase | $3.13 | +3,195 | 3,195 | New | +$10,000 | ||||||
2024-04-22 | ZURA | Zura Bio Ltd | Munshi Amit | Dir | P - Purchase | $3.13 | +159,744 | 777,384 | +26% | +$499,999 | ||||||
2024-04-22 | ZURA | Zura Bio Ltd | Sidhu Someit | Dir | P - Purchase | $3.13 | +1,186,901 | 3,675,047 | +48% | +$3,715,000 | ||||||
2024-04-22 | IPSC | Century Therapeutics, Inc. | Russotti Gregory | See Remarks | S - Sale | $3.10 | -5,000 | 390,092 | -1% | -$15,490 | ||||||
| AD | 2024-04-19 | INMB | Inmune Bio, Inc. | Moss David J | CFO, Treasurer, Secretary, 10% | P - Purchase | $8.32 | +18,028 | 1,268,179 | +1% | +$149,993 | |||||
| AD | 2024-04-19 | INMB | Inmune Bio, Inc. | Tesi Raymond Joseph | Pres, CEO, 10% | P - Purchase | $8.32 | +18,028 | 1,538,726 | +1% | +$149,993 | |||||
| AD | 2024-04-19 | INMB | Inmune Bio, Inc. | Lowdell Mark William | Chief Scientific Officer, 10% | P - Purchase | $8.32 | +14,423 | 1,510,806 | +1% | +$119,999 | |||||
| AD | 2024-04-19 | INMB | Inmune Bio, Inc. | Juda Scott | Dir | P - Purchase | $8.32 | +29,603 | 66,603 | +80% | +$246,297 | |||||
| M | 2024-04-19 | FRTX | Fresh Tracks Therapeutics, Inc. | Exploration Capital, LLC | 10% | P - Purchase | $0.90 | +21,528 | 1,107,807 | +2% | +$19,421 | |||||
| M | 2024-04-19 | ALVR | Allovir, Inc. | Hagen Brett R | Chief Accounting Officer | S - Sale | $0.75 | -953 | 77,619 | -1% | -$715 | |||||
| M | 2024-04-19 | ALVR | Allovir, Inc. | Miller Edward | GC | S - Sale | $0.75 | -1,383 | 512,026 | 0% | -$1,038 | |||||
2024-04-19 | ALVR | Allovir, Inc. | Brainard Diana | CEO | S - Sale | $0.75 | -9,601 | 802,935 | -1% | -$7,207 | ||||||
| M | 2024-04-19 | ALVR | Allovir, Inc. | Sinha Vikas | See Remarks, 10% | S - Sale | $0.75 | -3,378 | 17,812,862 | 0% | -$2,534 | |||||
| M | 2024-04-18 | PROK | Prokidney Corp. | Weber Darin J. | SVP of Regulatory Development | S - Sale | $2.51 | -17,238 | 155,194 | -10% | -$43,343 | |||||
| DM | 2024-04-19 | FENC | Fennec Pharmaceuticals Inc. | Haigh Adrian | COO | S - Sale+OE | $9.33 | -44,445 | 0 | -100% | -$414,472 | |||||
| D | 2024-04-18 | PCVX | Vaxcyte, Inc. | Guggenhime Andrew | Pres, CFO | S - Sale+OE | $61.27 | -8,000 | 95,679 | -8% | -$490,199 | |||||
2024-04-17 | MRNA | Moderna, Inc. | Afeyan Noubar | Dir | S - Sale | $103.38 | -15,000 | 11,722,969 | 0% | -$1,550,703 | ||||||
2024-04-17 | IMVT | Immunovant, Inc. | Levine Mark S. | GC | S - Sale | $29.06 | -9,827 | 347,119 | -3% | -$285,554 | ||||||
2024-04-17 | IMVT | Immunovant, Inc. | Macias William L. | Chief Medical Officer | S - Sale | $29.06 | -8,280 | 377,650 | -2% | -$240,602 | ||||||
2024-04-17 | IMVT | Immunovant, Inc. | Barnett Eva Renee | CFO | S - Sale | $29.06 | -12,253 | 359,456 | -3% | -$356,049 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |